Generation of Mouse Model of Hemophilia A by Introducing Novel Mutations, Using CRISPR/Nickase Gene Targeting System

Overview

Journal Cell J

Specialty Cell Biology

Date 2023 Sep 18

PMID 37718768

Authors

Mehdi Shamsara

Abbas Jamshidizad

Aidin Rahim-Tayefeh

Maliheh Davari

Ali Rajabi Zangi

Fatemeh Masoumi

Alireza Zomorodipour

Affiliations

Soon will be listed here.

Abstract

Developing mouse models of hemophilia A has been shown to facilitate studies to explore the probable mechanism(s) underlying the disease and to examine the efficiency of the relevant potential therapeutics. This study aimed to knockout (KO) the gene in NMRI mice, using CRISPR/Cas9 (D10A/nickase) system, to generate a mouse model of hemophilia A. Two single guide RNAs (sgRNAs), designed from two distinct regions on NMRI mouse exon 3, were designed and inserted in the pX335 vector, expressing both sgRNAs and nickase. The recombinant construct was delivered into mouse zygotes and implanted into the pseudopregnant female mice's uterus. Mutant mice were identified by genotyping, genomic sequencing, and mFVIII activity assessment. Two separate lines of hemophilia A were obtained through interbreeding the offspring of the female mice receiving potential CRISPR-Cas9-edited zygotes. Genomic DNA analysis revealed disruptions of the mfviii gene reading frame through a 22-bp deletion and a 23-bp insertion in two separate founder mice. The founder mice showed all the clinical signs of hemophilia A including; excessive bleeding after injuries, and spontaneous bleeding in joints and other organs. Coagulation test data showed that mFVIII coagulation activity was significantly diminished in the mFVIII knockout (FVIII) mice compared to normal mice. The CRISPR/nickase system was successfully applied to generate mouse lines with the knockout fviii gene. The two novel FVIII mice demonstrated all clinical symptoms of hemophilia A, which could be successfully inherited. Therefore, both of the developed FVIII mouse lines are eligible for being considered as proper mouse models of hemophilia A for in vivo therapeutic studies.

References

Bi L, Lawler A, Antonarakis S, High K, Gearhart J, Kazazian Jr H . Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995; 10(1):119-21. DOI: 10.1038/ng0595-119. View

Turecek P, Gritsch H, Richter G, Auer W, Pichler L, Schwarz H . Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease. Thromb Haemost. 1997; 77(3):591-9. View

Bi L, Sarkar R, Naas T, Lawler A, Pain J, Shumaker S . Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood. 1996; 88(9):3446-50. View

Kaufman R, Dorner A, Fass D . von Willebrand factor elevates plasma factor VIII without induction of factor VIII messenger RNA in the liver. Blood. 1998; 93(1):193-7. View

Gama Sosa M, De Gasperi R, Elder G . Animal transgenesis: an overview. Brain Struct Funct. 2009; 214(2-3):91-109. DOI: 10.1007/s00429-009-0230-8. View

Porada C, Sanada C, Long C, Wood J, Desai J, Frederick N . Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. J Thromb Haemost. 2009; 8(2):276-85. PMC: 2826196. DOI: 10.1111/j.1538-7836.2009.03697.x. View

Hall B, Limaye A, Kulkarni A . Overview: generation of gene knockout mice. Curr Protoc Cell Biol. 2009; Chapter 19:Unit 19.12 19.12.1-17. PMC: 2782548. DOI: 10.1002/0471143030.cb1912s44. View

Ovlisen K, Kristensen A, Tranholm M . In vivo models of haemophilia - status on current knowledge of clinical phenotypes and therapeutic interventions. Haemophilia. 2008; 14(2):248-59. DOI: 10.1111/j.1365-2516.2007.01636.x. View

Santacroce R, Acquila M, Belvini D, Castaldo G, Garagiola I, Giacomelli S . Identification of 217 unreported mutations in the F8 gene in a group of 1,410 unselected Italian patients with hemophilia A. J Hum Genet. 2008; 53(3):275-284. DOI: 10.1007/s10038-007-0238-y. View

10.

Notley C, Killoran A, Cameron C, Wynd K, Hough C, Lillicrap D . The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo. Hum Gene Ther. 2002; 13(13):1583-93. DOI: 10.1089/10430340260201671. View

11.

Batty P, Lillicrap D . Hemophilia Gene Therapy: Approaching the First Licensed Product. Hemasphere. 2021; 5(3):e540. PMC: 7886458. DOI: 10.1097/HS9.0000000000000540. View

12.

Sarkar R, Gao G, Chirmule N, Tazelaar J, Kazazian Jr H . Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. Hum Gene Ther. 2000; 11(6):881-94. DOI: 10.1089/10430340050015491. View

13.

De Brasi C, Slavutsky I, Larripa I . [Molecular genetics of hemophilia A]. Medicina (B Aires). 1996; 56(5 Pt 1):509-17. View

14.

Ran F, Hsu P, Lin C, Gootenberg J, Konermann S, Trevino A . Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013; 154(6):1380-9. PMC: 3856256. DOI: 10.1016/j.cell.2013.08.021. View

15.

Luo L, Zheng Q, Chen Z, Huang M, Fu L, Hu J . Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications. Front Immunol. 2022; 13:1019275. PMC: 9774473. DOI: 10.3389/fimmu.2022.1019275. View

16.

Dow L . Modeling Disease In Vivo With CRISPR/Cas9. Trends Mol Med. 2015; 21(10):609-621. PMC: 4592741. DOI: 10.1016/j.molmed.2015.07.006. View

17.

Sabatino D, Nichols T, Merricks E, Bellinger D, Herzog R, Monahan P . Animal models of hemophilia. Prog Mol Biol Transl Sci. 2011; 105:151-209. PMC: 3713797. DOI: 10.1016/B978-0-12-394596-9.00006-8. View

18.

Kashiwakura Y, Mimuro J, Onishi A, Iwamoto M, Madoiwa S, Fuchimoto D . Porcine model of hemophilia A. PLoS One. 2012; 7(11):e49450. PMC: 3509096. DOI: 10.1371/journal.pone.0049450. View

19.

Austin C, Battey J, Bradley A, Bucan M, Capecchi M, Collins F . The knockout mouse project. Nat Genet. 2004; 36(9):921-4. PMC: 2716027. DOI: 10.1038/ng0904-921. View

20.

Yen C, Fan M, Yang Y, Chou S, Yu I, Lin S . Current animal models of hemophilia: the state of the art. Thromb J. 2016; 14(Suppl 1):22. PMC: 5056469. DOI: 10.1186/s12959-016-0106-0. View